Citigroup’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-56,344
| Closed | -$509K | – | 6437 |
|
|
2025
Q4 | $509K | Buy |
56,344
+53,871
| +2,178% | +$403K | ﹤0.01% | 3563 |
|
|
2025
Q3 | $7.69K | Sell |
2,473
-43,857
| -95% | -$116K | ﹤0.01% | 5094 |
|
|
2025
Q2 | $99.1K | Buy |
46,330
+1,278
| +3% | +$2.06K | ﹤0.01% | 4407 |
|
|
2025
Q1 | $51.8K | Sell |
45,052
-11,952
| -21% | -$20.5K | ﹤0.01% | 4857 |
|
|
2024
Q4 | $125K | Buy |
57,004
+11,056
| +24% | +$25.1K | ﹤0.01% | 4718 |
|
|
2024
Q3 | $100K | Buy |
45,948
+28,093
| +157% | +$64.6K | ﹤0.01% | 4762 |
|
|
2024
Q2 | $41.2K | Buy |
17,855
+5,992
| +51% | +$24.9K | ﹤0.01% | 4697 |
|
|
2024
Q1 | $65.2K | Buy |
11,863
+2,049
| +21% | +$9.37K | ﹤0.01% | 4496 |
|
|
2023
Q4 | $24.2K | Sell |
9,814
-329
| -3% | -$3.13K | ﹤0.01% | 4908 |
|
|
2023
Q3 | $352K | Sell |
10,143
-35,507
| -78% | -$1.23M | ﹤0.01% | 3313 |
|
|
2023
Q2 | $1.5M | Buy |
45,650
+36,388
| +393% | +$1.25M | ﹤0.01% | 2494 |
|
|
2023
Q1 | $310K | Buy |
9,262
+4,345
| +88% | +$169K | ﹤0.01% | 3474 |
|
|
2022
Q4 | $161K | Buy |
4,917
+2,509
| +104% | +$74.3K | ﹤0.01% | 3827 |
|
|
2022
Q3 | $84K | Sell |
2,408
-122,104
| -98% | -$2.7M | ﹤0.01% | 4172 |
|
|
2022
Q2 | $1.52M | Buy |
124,512
+124,105
| +30,493% | +$1.85M | ﹤0.01% | 2312 |
|
|
2022
Q1 | $6K | Sell |
407
-2,419
| -86% | -$32.3K | ﹤0.01% | 5771 |
|
|
2021
Q4 | $56K | Buy |
+2,826
| New | +$53.6K | ﹤0.01% | 5007 |
|
Other funds holding VTYX
Citigroup's VTYX Position: Q1 2026 in Review
Citigroup sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 56,344 shares — an estimated $509K sold.
Citigroup first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $1.52M in Q2 2022. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Citigroup reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Citigroup sold 56,344 Ventyx Biosciences shares in Q1 2026, an estimated $509K.
- Citigroup first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
- Citigroup's Ventyx Biosciences position peaked at $1.52M in Q2 2022.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.